Akari Therapeutics Plc (AKTX) shares soared 89.01 percent to $9.72, up $4.58 on Friday, likely continuing momentum from the company's recently announced positive preclinical oncology data ahead of the American Society of Clinical Oncology Annual Meeting 2026.
The stock is currently trading at $9.72, compared with a previous close of $5.14 on the Nasdaq. It opened at $9.91 and traded between $8.78 and $10.91 during the session, with volume reaching 10.88 million shares, far above the average daily volume of 68,240 shares.
Akari Therapeutics Plc said new data showed its lead antibody-drug conjugate candidate, AKTX-101, demonstrated synergistic anti-cancer activity when combined with the KRAS inhibitor adagrasib in KRAS-mutated pancreatic cancer models.
The company said the studies showed enhanced cell killing in KRAS G12C and KRAS G12D mutant cancer cell lines, while comparator TROP2-targeting therapies displayed antagonistic effects in combination testing.
Akari Therapeutics shares have traded between $3.02 and $56.80 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.